Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board
March 10 2020 - 8:05AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced that Zachariah P. Zachariah,
M.D., a Florida-based cardiologist, joined the Advisory Board of
the Company.
Currently, Dr. Zachariah serves as a Chairman of the Florida
Board of Medicine, as a member of the National Heart, Lung and
Blood Institute of the National Institute of Health. He also serves
as a member of the Board of Trustees of Nova Southeastern
University, a member of the Council of 100 and as a member of the
National Board of ExcelinED in Action.
Previously, Dr. Zachariah served on the Florida Board of
Governors of the State University system from 2003 to 2010 and from
2017 to May 2019. He has been practicing interventional cardiology
at Holy Cross Hospital since 1976 and as its Director of
Cardiovascular Services until 2010. He has also served on the
National Heart, Lung and Blood Institute at the National Institutes
of Health from 1990 to 1993 and as a member of the U.S. delegation
to the World Health Organization in Geneva, Switzerland. He also
served as Chairman of the Florida Board of Medicine from 1990-1992,
2000-2001 and 2013-2014. He also served as a member of the
President’s Advisory Commission on Asian Americans and Pacific
Islanders appointed by President George W. Bush in 2001.
Dr. Zachariah is board-certified in internal medicine and
cardiology and specializes in cardiology, cardiac catheterization,
and interventional cardiology and has performed more than 30,000
heart catheterizations and interventional procedures in Broward
County. He co-authored several scientific papers, and participated
in various clinical trials.
He received his medical degree from the Armed Forces Medical
College in India, and then completed his residency at St. Joseph’s
Hospital and Medical Center in Paterson, New Jersey. He also
completed a fellowship in interventional cardiology at the
Cleveland Clinic Educational Foundation in Cleveland, Ohio.
“Having been able to see PURE EP™ System in the clinical lab, I
was immediately impressed by the impact this technology delievered
in real-time. It is very obvious to me that BioSig is addressing an
urgent clinical need, and I look forward to contributing my
expertise to advance the Company’s growth,” commented Dr.
Zachariah.
Dr. Zachariah is a holder of numerous awards, including the
Ellis Island American Legend Award, the Golden Heart Award from the
American Heart Association, Freedom Foundation Medal of Honor from
the Freedom Foundation at Valley Forge, and Ellis Island Medal of
Honor. “We are delighted that Dr. Zachariah is joining our Advisory
Board at this important time. As we begin to commercialize PURE EP
System, we believe Dr. Zachariah’s clinical expertise and
first-hand knowledge of nationwide hospital systems will be a
definite advantage to our clinical operations, ” commented Kenneth
L. Londoner, Chairman and CEO of BioSig Technologies, Inc. The goal
of the Company’s Advisory Board is to advise the leadership on a
range of subjects, including commercialization, financing,
strategy, marketing, government affairs and partnerships. Current
members of the Board include Mr. Sim Farar, a political advisor and
business leader, Mr. Kent Bennett Williams, CEO and Principal at
Vista Asset Management, LLC, Dr. Ramachandra Malya, a medical
director, D.A. Wallach, an investor, recording artist and
songwriter, and Mr. Frank J. Quintero, a principal at the Yucaipa
Companies.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024